key: cord-0944131-3y4s48eu
authors: Dehgani-Mobaraki, P.; Kamber Zaidi, A.; Porreca, A.; Floridi, A.; Floridi, E.
title: Neutralizing antibody responses 10 months after mild and moderately-severe SARS-CoV-2 infection
date: 2021-02-23
journal: nan
DOI: 10.1101/2021.02.22.21252225
sha: 25549f96aaba3c1dbc447b457faa9f558ca99b7a
doc_id: 944131
cord_uid: 3y4s48eu

Improved understanding of immunity offered by the antibodies developed against SARS-CoV-2 is critical. Our study aimed at longitudinal analysis of presence and persistence of neutralizing antibodies over ten months in mild and moderately-severe COVID-19 recovered patients using two immunoassays.

The year 2021 began with large-scale rollout of vaccines against COVID-19 and the preliminary results in terms of acquired immunity post-vaccination have shown good results with reduction in the rate of infections and deaths. (1) However, long-term immunity in recovered patients is still a dilemma. Studies have shown the persistency of humoral immune response ranging from three months to more than eight months. (2, 3) We evaluated the antibody responses of 30 people, based in the Umbria region in Italy, post severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, over 10 months through six sequential serological tests.

The study: A monocentric pilot longitudinal observational study was conducted on 114 participants, who had tested positive by real-time quantitative polymerase chain reaction (RT-PCR) for SARS-CoV-2 in the period between 1-30 March 2020. Written informed consent was obtained by all participants for voluntary participation in this study.The demographic characteristics, blood groups, co-morbidities, clinical features, treatment undertaken, and dates pertaining to symptom onset and RT-PCR tests were recorded. Sequential serum samples were collected over a period of ten months through six serial blood tests at appropriate intervals for 30 out of the 114 subjects who attended all the follow-up visits.

The aim of this study was to investigate for presence and persistency of SARS-CoV-2 specific antibodies over ten months using two commercial immunoassays :The MAGLUMI® 2019-nCoV lgM/lgG chemiluminescent analytical system (CLIA) Assay (4) for the first five tests and MAGLUMI® SARS-CoV-2 S-RBD IgG Chemiluminescence immunoassay (CLIA) for the last test. (5) These immunoassays were granted Emergency Use Authorization by the US Food and Drug Administration. Measurements and interpretation of results were made according . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Moderately-Severe). Chi-squared test was used to measure the association between the severity groups and the categorical variables. The Mann U Whitney test was used to assess the differences between groups for the continuous variables at each time point. Shapiro Wilks tested the normal distribution of the data. The Friedman test was applied to look for statistically significant differences over time within the two severity groups for both IgM and IgG. All tests were two-sided, and a level of statistical significance was set at p<0.05. All the statistical analyses were performed using R software environment for statistical computing and graphics version 3.5.2 (R Foundation for Statistical Computing, Vienna, Austria;https://www.Rproject.org/)

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 23, 2021. ;

Results : The data from 30 participants who had tested positive for SARS-CoV-2 infection were analyzed. The descriptive statistics for the main characteristics of the study group are reported in Table 1 . The IgM and IgG titres divided into Mild (n=17) and Moderately-severe groups (n=13), expressed as a median [1st -3rd ] are reported in Table 2 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 23, 2021. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 23, 2021. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 23, 2021. ; https://doi.org/10.1101/2021.02.22.21252225 doi: medRxiv preprint

It works: 0 deaths, only 4 severe cases among 523,000 fully vaccinated

A comprehensive analysis of recovered COVID-19 patients and dynamic trend in antibodies over 3 months using ELISA and CLIA methods

Antibody responses 8 months after asymptomatic or mild SARS-CoV-2 infection. Emerg Infect Dis

Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19

Rapid detection of SARS-CoV-2-specific memory T-cell immunity in recovered COVID-19 cases

Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence

Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis